Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses
MarketBeat
Clene (NASDAQ:CLNN) is preparing to submit a New Drug Application, or NDA, seeking accelerated approval for CNM-Au8 in amyotrophic lateral sclerosis, or ALS, after completing additional analyses requested by the U.S. Food and Drug Administration, President and CEO Rob Etherington said in an intervie
NASDAQ:CLNN